Back to today’s briefing

Story perspectives

DoD Invests in mRNA Vaccines Amid Funding Cuts

9/25/2025

49 9

Summary

Story summary

The U.S. Department of Defense (DoD) continues funding mRNA vaccine work to protect soldiers, despite nearly $500 million in cuts.
Cuts raise concerns about long-term commitment to the Crimean–Congo haemorrhagic fever (CCHF) vaccine work.
HDT Bio's CCHF vaccine trial halted, then resumed with DoD support.
Moderna is developing an mRNA Marburg vaccine tied to a Tanzania outbreak.

1 of 1

Story summary

The U.S. Department of Defense (DoD) continues funding mRNA vaccine work to protect soldiers, despite nearly $500 million in cuts.
Cuts raise concerns about long-term commitment to the Crimean–Congo haemorrhagic fever (CCHF) vaccine work.
HDT Bio's CCHF vaccine trial halted, then resumed with DoD support.
Moderna is developing an mRNA Marburg vaccine tied to a Tanzania outbreak.